Program:
The development and evaluation of effective treatments for AIDS is highly dependent on the capability of quickly determining the clinical effectiveness of a given approach. While reliance on long-term mortality impact is the most reliable measure, other measures that can rapidly provide a strong indication of performance are needed. A general consensus from earlier conferences is that surrogate markers of viral activity and of immunological function will be needed to serve this purpose. Experience with the use of plasma HIV RNA levels and possible ways of improving upon viral load as a marker for viral activity will be featured. The sometimes weak correlation of CD4+ cell counts with prognosis and immunological function indicates that additional markers or alternative measures are needed to better predict risk of progression. Results from clinical trials in which viral load and other markers have been studied will also be highlighted.
Registration :
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164 USA
tel: 617-630-1300
fax: 617-630-1325
Deadline for Abstracts: 9/96
Email for Requests and Registration: chi@healthtech.com